Skip to content
Screener

Charles River Laboratories CRL Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Revvity logo
RevvityRVTY
$0—
IQVIA logo
IQVIAIQV
$1.11B-44.6%
Quest Diagnostics logo
Quest DiagnosticsDGX
$494M+167%
NeoGenomics logo
NeoGenomicsNEO
$0—
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$0—
Danaher logo
DanaherDHR
$6.56B—

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-6%—
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%—
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemSix Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Other, net(1,298)347
Net cash used in investing activities(379,748)(82,818)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility1,265,258963,363
Payments on long-term debt, revolving credit facility, and finance lease obligations(745,927)(887,706)
Proceeds from exercises of stock options1,6201
Purchase of treasury stock(323,881)(360,484)
Payments of contingent consideration(11,400)(21,822)

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's debt issuance proceeds?
Charles River Laboratories (CRL) reported debt issuance proceeds of $352.8M in Q2 2026.
How has Charles River Laboratories's debt issuance proceeds changed year-over-year?
Charles River Laboratories's debt issuance proceeds decreased by 35.5% year-over-year, from $547.02M to $352.8M.
What is the long-term trend for Charles River Laboratories's debt issuance proceeds?
Over 4 years (2021 to 2025), Charles River Laboratories's debt issuance proceeds has grown at a -35.2% compound annual growth rate (CAGR), from $6.95B to $1.23B.
What does debt issuance proceeds mean?
Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

Ask your AI about Charles River Laboratories's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude